The Latest Breaking News from Foundayo

Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Counted

A Lilly-funded modeling analysis tied Foundayo to a 57% lower predicted 10-year diabetes risk. No actual diabetes cases were counted in the study.

Medical Daily · Oct 3

Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysis

Lilly's indirect analysis found Foundayo 17.2 mg edged oral semaglutide 25 mg on weight and A1C in type 2 diabetes, but the gaps were modest.

Medical Daily · Oct 1

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

International Business Times · Aug 5

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

MarketBeat · May 1

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means

Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.

MarketBeat · Apr 28

UAE introduces first-ever weight loss pill Foundayo, here’s how much it may cost and where to get it

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026,…

The Times of India · Apr 17

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Barchart · Apr 1